Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd

SZSE:301126 Stock Report

Market Cap: CN¥2.5b

Hunan Dajiaweikang Pharmaceutical IndustryLtd Valuation

Is 301126 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301126 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301126 (CN¥11.94) is trading above our estimate of fair value (CN¥0.56)

Significantly Below Fair Value: 301126 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301126?

Key metric: As 301126 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301126. This is calculated by dividing 301126's market cap by their current earnings.
What is 301126's PE Ratio?
PE Ratio52.3x
EarningsCN¥46.93m
Market CapCN¥2.45b

Price to Earnings Ratio vs Peers

How does 301126's PE Ratio compare to its peers?

The above table shows the PE ratio for 301126 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average86.7x
301166 Shanghai Universal BiotechLtd
185.4xn/aCN¥2.6b
000705 Zhejiang Zhenyuan ShareLtd
51.2xn/aCN¥2.8b
002788 Luyan PharmaLtd
9.5xn/aCN¥3.4b
603122 Cowealth Medical ChinaLtd
100.6xn/aCN¥3.0b
301126 Hunan Dajiaweikang Pharmaceutical IndustryLtd
52.3xn/aCN¥2.5b

Price-To-Earnings vs Peers: 301126 is good value based on its Price-To-Earnings Ratio (52.3x) compared to the peer average (86.7x).

Price to Earnings Ratio vs Industry

How does 301126's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
301126 52.3xIndustry Avg. 33.5xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 301126 is expensive based on its Price-To-Earnings Ratio (52.3x) compared to the CN Healthcare industry average (33.5x).

Price to Earnings Ratio vs Fair Ratio

What is 301126's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301126 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio52.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 301126's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Chison Medical Technologies

CN¥3.0b

Manufactures and sells diagnostic ultrasound systems in China and internationally.

688358

CN¥26.27

7D

1.8%

1Y

-39.3%

Truking Technology

CN¥4.7b

Engages in medical equipment business in China and internationally.

300358

CN¥7.95

7D

-0.7%

1Y

-31.8%

iRay Technology

CN¥16.0b

Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.

688301

CN¥111.99

7D

-0.8%

1Y

-28.0%